ROCKVILLE, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics…
Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents…
Placebo-controlled Phase 2 trial cleared by the FDA – Trial to begin in Q2 2024 Trial to include Schizophrenia validated…
NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing…
Submission of Complete Response to Clinical Hold for HEMO-CAR-T INDLONDON, UK / ACCESSWIRE / January 16, 2024 / Hemogenyx Pharmaceuticals…
TORONTO, ON / ACCESSWIRE / January 15, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ")…
SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic…
Cell BioEngines, Inc moves to Manhattan, New York, to leverage the city’s focus and strategic investment in biotechNEW YORK, Jan.…
TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage…
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or…